The Medical Letter on Drugs and Therapeutics
ADVANCE
RELEASE
ARTICLE
September 3, 2024
View Complete Issue         Table of Contents 2019 
Vonoprazan (Voquezna) for Nonerosive GERD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Vonoprazan (Voquezna) for Nonerosive GERD
September 3, 2024 (Issue: 5083)
The potassium-competitive acid blocker vonoprazan (Voquezna – Phathom), which was approved earlier for treatment of erosive esophagitis, has now been approved by the FDA for relief of heartburn associated with nonerosive gastroesophageal reflux...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Vonoprazan (Voquezna) for Nonerosive GERD
Article code: 5083a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.